Cargando…
SAT099 Should We Use HbA1c Or Continuous Glucose Monitoring (CGM) For Treatment Adjustment In Type 2 Diabetes Non-insulin Treated Patients?
Disclosure: T. Totomirova: None. M. Arnaudova: None. Current recommendations include treatment changes in type 2 non-insulin patients to be based preferably on HbA1c. HbA1c shows insufficiency as glucose control assessment tool omitting glucose fluctuations and hypoglycemic episodes. Continuous gluc...
Autores principales: | Totomirova, Tzvetelina, Arnaudova, Mila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553404/ http://dx.doi.org/10.1210/jendso/bvad114.965 |
Ejemplares similares
-
SAT-126 The Relationship of Continuous Glucose Monitoring (CGM)-Derived Time-in-Range (TIR) to Hemoglobin A1c (HbA1c)
por: Vigersky, Robert, et al.
Publicado: (2019) -
ODP211 Impact of Race and Chronic Kidney Disease on the Correlation between HbA1c and Continuous Glucose Monitoring (CGM) Glycemic Measures
por: Kaplan, Leah, et al.
Publicado: (2022) -
SAT115 Diabetes In Pregnancy: Evaluating Access And Usage Of Continuous Glucose Monitors (CGM) In A Medicaid Population
por: Chilukuri, Pranaya, et al.
Publicado: (2023) -
SAT134 CGM Use During Pregnancy Complicated By CF-Induced Diabetes
por: Mazori, Alon Y, et al.
Publicado: (2023) -
SAT152 Retrospective Analysis Of HbA1c In Patients Diagnosed With Pancreatic Insulinoma Prior To- And After Surgical Excision
por: Lawless, Sarah Jean, et al.
Publicado: (2023)